Independent Peptide Analysis
Evidence-based analysis, vendor accountability, and honest guidance in a market flooded with marketing claims. No vendor sponsorship. No pay-for-play reviews.
Monthly roundup: RFK Jr. announces reclassification of 14 Category 2 peptides, Hims & Hers confirms peptide product line, and peptides go mainstream.
Monthly roundup: MIT Technology Review's peptide feature, RFK Jr.'s FDA influence, Chinese import crackdown, and regulatory uncertainty.
Evidence-based analysis of sermorelin + testosterone therapy. What studies show about GH-testosterone synergy and body composition.
Timeline of FDA enforcement actions against peptide vendors from 2023-2026: warning letters, criminal cases, and regulatory changes.
Complete timeline of FDA and ITC enforcement actions against peptide vendors from 2024-2026. Warning letters, exclusion orders, and the BPC-157 ban.
Oral BPC-157 vendors rated on transparency, third-party testing, value, and regulatory compliance. Updated quarterly.
Ratings reflect our independent analysis. Vendors cannot pay to improve their scores. See our methodology.
Evidence-rated profiles for every major peptide. What the research shows, what it doesn't, and what vendors won't tell you.
Weekly analysis of the peptide market: regulatory changes, vendor evaluations, research updates, and the news that matters. Zero vendor influence.